Rebus Holdings Inc (RBSH)

[Mrragu]

There is really not much to update other than what little we all get in the filings. Mipsagargin the first and original drug that spawned interest in GNSZ/NSPX and now RBSH has been on the shelve for a few yrs. Although fairly well received in Ph II trials it never has got the necessary financing to progress into PH III. Currently RBSH has hitched its success to adenosine receptor antagonist RT-AR001. The drug has completed in VITRO studies and RBSH has contracted suppliers to manufacture enough of the drug to carry thru the next step in VIVO studies and once approved start clinical trials. As usual for clinical stage bios money is the problem. RBSH is currently out of cash and needs financing to carry out the plans set forth in the filings. The CEO Raul Silvestre is currently financing the necessary expenses to provide the SEC with the necessary filings and is accruing those expenses. Silvestre Law group is owed over $300K and also holds a $290K convertible loan (debenture). Hopefully, the next few months will provide some financing news and RT-AR001 can move forward on the way to FDA approval.